Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions


      • The detection of PDGFRA rearrangements in myeloid/lymphoid neoplasms is critical for patient medical management.
      • Chromosomes and the FIP1L1/CHIC2/PDGFRA FISH probe set are insufficient to characterize t(4;12)(q12;p13) in hematologic neoplasms.
      • Next generation sequencing outperforms traditional cytogenetic techniques in the molecular characterization of t(4;12)(q12;p13).


      The t(4;12)(q12;p13) has been rarely reported in both myeloid/lymphoid neoplasms with eosinophilia (ETV6/PDGFRA gene fusion) and acute myeloid leukemia (AML) (ETV6/CHIC2 gene fusion). The ability to accurately characterize t(4;12) is critical as myeloid neoplasms with PDGFRA rearrangements may be amenable to tyrosine kinase inhibitor (TKI) therapy. Herein, we describe a 60-year-old male with newly diagnosed AML and t(4;12)(q12;p13) by conventional chromosome studies. While the ETV6 break-apart fluorescence in situ hybridization (FISH) probe set demonstrated a balanced ETV6 gene rearrangement, the FIP1L1/CHIC2/PDGFRA tri-color and PDGFRA break-apart FISH probe sets could not resolve the ETV6 gene fusion partner. Mate-pair sequencing (MPseq), a next-generation sequencing assay, was subsequently performed and identified an ETV6 gene rearrangement (at 12p13) that involved an intergenic chromosomal region at 4q12, located between the CHIC2 and PDGFRA gene regions. Having excluded involvement by the PDGFRA gene region, the patient will not be considered for TKI therapy at any point during his medical management. The accurate characterization of structural rearrangements by NGS-based technologies, as demonstrated in this case, highlights the clinical relevance and potential impact on patient medical management of modern cytogenetic techniques.


      To read this article in full you will need to make a payment


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Drucker TM
        • Johnson SH
        • Murphy SJ
        • et al.
        BIMA V3: an aligner customized for mate pair library sequencing.
        Bioinformatics. 2014; 30: 1627-1629
        • Johnson SH
        • Smadbeck JB
        • Smoley SA
        • et al.
        SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq).
        Cancer Genet. 2018; 221: 1-18
        • Bain BJ
        • Horny HP
        • Arber DA
        • Tefferi A
        • Hasserjian RP.
        • et al.
        Myeloid/lymphoid neoplasms with eosinophilia and rearrangements of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2.
        in: Swerdlow SH Campo E Harris NL WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer (IARC), Lyon, France2017: 72-79
        • Metzgeroth G
        • Walz C
        • Score J
        • et al.
        Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
        Leukemia. 2007; 21: 1183-1188
        • Jain N
        • Khoury JD
        • Pemmaraju N
        • et al.
        Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
        Blood. 2013; 122: 3387-3388
        • Rudzki Z
        • Giles L
        • Cross NCP
        • et al.
        Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity?.
        Br J Haematol. 2012; 156: 558
        • Curtis CE
        • Grand FH
        • Musto P
        • et al.
        Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.
        Br J Haematol. 2007; 138: 77-81
        • Chalmers ZR
        • Ali SM
        • Ohgami RS
        • et al.
        Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
        Blood Cancer J. 2015; 5: e278
        • Sugimoto Y
        • Sada A
        • Shimokariya Y
        • et al.
        A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia.
        Cancer Genet. 2015; 208: 508-512
        • Kuchenbauer F
        • Schoch C
        • Holler E
        • et al.
        A rare case of acute myeloid leukemia with a CHIC2-ETV6 fusiongene and multiple other molecular aberrations.
        Leukemia. 2005; 19: 2366-2368
        • Cools J
        • Bilhou-Nabera C
        • Wlodarska I
        • et al.
        Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12)(q11-q12;p13).
        Blood. 1999; 94: 1820-1824
        • Cools J
        • Mentens N
        • Odero MD
        • et al.
        Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13).
        Blood. 2002; 99: 1776-1784
        • Mueller SB
        • Dal Cin P
        • Le LP
        • et al.
        t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.
        Blood Adv. 2021; (In press)https://doi.org/10.1182/bloodadvances.2021005280
        • Peterson JF
        • Blackburn PR
        • Webley MR
        • et al.
        Identification of a novel ZBTB20-JAK2 fusion by mate-pair sequencing in a young adult with B-lymphoblastic leukemia/lymphoma.
        Mayo Clin Proc. 2019; 94: 1381-1384
        • Smadbeck J
        • Peterson JF
        • Pearce KE
        • et al.
        Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma.
        Blood Cancer J. 2019; 9: 103
        • Lopes JL
        • Webley M
        • Pitel BA
        • et al.
        Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis.
        Cancer Genet. 2020; 243: 48-51
        • Aypar U
        • Smoley SA
        • Pitel BA
        • et al.
        Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.
        Eur J Haematol. 2019; 102: 87-96